These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37453238)

  • 1. Chemical metabolite synthesis and profiling: Mimicking in vivo biotransformation reactions.
    Chhatrapati Bisen A; Nashik Sanap S; Agrawal S; Biswas A; Sankar Bhatta R
    Bioorg Chem; 2023 Oct; 139():106722. PubMed ID: 37453238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
    Orhan H; Vermeulen NP
    Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
    Obach RS
    Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.
    Blanz J; Williams G; Dayer J; Délémonté T; Gertsch W; Ramstein P; Aichholz R; Trunzer M; Pearson D
    J Mass Spectrom; 2017 Apr; 52(4):210-217. PubMed ID: 28152561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective Application of Metabolite Profiling in Drug Design and Discovery.
    Cerny MA; Kalgutkar AS; Obach RS; Sharma R; Spracklin DK; Walker GS
    J Med Chem; 2020 Jun; 63(12):6387-6406. PubMed ID: 32097005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the challenge of chemically reactive metabolites in drug development.
    Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; Naisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA
    Nat Rev Drug Discov; 2011 Apr; 10(4):292-306. PubMed ID: 21455238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule drug metabolite synthesis and identification: why, when and how?
    Shanu-Wilson J; Coe S; Evans L; Steele J; Wrigley S
    Drug Discov Today; 2024 May; 29(5):103943. PubMed ID: 38452922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial biotransformation - an important tool for the study of drug metabolism.
    Salter R; Beshore DC; Colletti SL; Evans L; Gong Y; Helmy R; Liu Y; Maciolek CM; Martin G; Pajkovic N; Phipps R; Small J; Steele J; de Vries R; Williams H; Martin IJ
    Xenobiotica; 2019 Aug; 49(8):877-886. PubMed ID: 30118378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing around Structural Alerts in Drug Discovery.
    Kalgutkar AS
    J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of mass spectrometry for metabolite identification.
    Ma S; Chowdhury SK; Alton KB
    Curr Drug Metab; 2006 Jun; 7(5):503-23. PubMed ID: 16787159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical tools and approaches for metabolite identification in early drug discovery.
    Chen Y; Monshouwer M; Fitch WL
    Pharm Res; 2007 Feb; 24(2):248-57. PubMed ID: 17048114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J; Hayes MA; Thompson RA; Weidolf L; Isin EM
    Drug Metab Dispos; 2016 May; 44(5):732-40. PubMed ID: 26868617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.